Zhejiang Hisun Pharma has in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal that totals $100 million in upfront and milestone payments. Celsion is expected to announce results from a Phase III trial of the drug later this month. In May 2012, Celsion chose Hisun as its global manufacturer for ThermoDox. Celsion expects the deal to be worth “hundreds of million of dollars” over time in milestones and royalties, given the prevalence of liver cancer in China. More details.... Stock Symbols: (SHA: 600267) (NSDQ: CLSN) Share this with colleagues: // //